These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10688977)

  • 1. Cellular uptake and interaction with purified membranes of rebeccamycin derivatives.
    Goossens JF; Hénichart JP; Anizon F; Prudhomme M; Dugave C; Riou J; Bailly C
    Eur J Pharmacol; 2000 Feb; 389(2-3):141-6. PubMed ID: 10688977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA binding and topoisomerase I poisoning activities of novel disaccharide indolocarbazoles.
    Facompre M; Carrasco C; Colson P; Houssier C; Chisholm JD; Van Vranken DL; Bailly C
    Mol Pharmacol; 2002 Nov; 62(5):1215-27. PubMed ID: 12391286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
    Anizon F; Belin L; Moreau P; Sancelme M; Voldoire A; Prudhomme M; Ollier M; Sevère D; Riou JF; Bailly C; Fabbro D; Meyer T
    J Med Chem; 1997 Oct; 40(21):3456-65. PubMed ID: 9341921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
    Bailly C; Riou JF; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M
    Biochemistry; 1997 Apr; 36(13):3917-29. PubMed ID: 9092822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calories from carbohydrates: energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition.
    Bailly C; Qu X; Graves DE; Prudhomme M; Chaires JB
    Chem Biol; 1999 May; 6(5):277-86. PubMed ID: 10322124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rebeccamycin analogues from indolo[2,3-c]carbazole.
    Voldoire A; Sancelme M; Prudhomme M; Colson P; Houssier C; Bailly C; Léonce S; Lambel S
    Bioorg Med Chem; 2001 Feb; 9(2):357-65. PubMed ID: 11249128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue.
    Bailly C; Qu X; Anizon F; Prudhomme M; Riou JF; Chaires JB
    Mol Pharmacol; 1999 Feb; 55(2):377-85. PubMed ID: 9927631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle.
    Moreau P; Anizon F; Sancelme M; Prudhomme M; Bailly C; Carrasco C; Ollier M; Sevère D; Riou JF; Fabbro D; Meyer T; Aubertin AM
    J Med Chem; 1998 May; 41(10):1631-40. PubMed ID: 9572888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin.
    Bailly C; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M; Waring MJ
    Mol Pharmacol; 1998 Jan; 53(1):77-87. PubMed ID: 9443934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.
    Vanhoefer U; Voigt W; Hilger RA; Yin MB; Harstrick A; Seeber S; Rustum YM
    Oncol Res; 1997; 9(9):485-94. PubMed ID: 9495454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formaldehyde-induced alkylation of a 2'-aminoglucose rebeccamycin derivative to both A.T and G.C base pairs in DNA.
    Bailly C; Goossens JF; Laine W; Anizon F; Prudhomme M; Ren J; Chaires JB
    J Med Chem; 2000 Nov; 43(24):4711-20. PubMed ID: 11101362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
    Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
    Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syntheses, biochemical and biological evaluation of staurosporine analogues from the microbial metabolite rebeccamycin.
    Anizon F; Moreau P; Sancelme M; Voldoire A; Prudhomme M; Ollier M; Sevère D; Riou JF; Bailly C; Fabbro D; Meyer T; Aubertin AM
    Bioorg Med Chem; 1998 Sep; 6(9):1597-604. PubMed ID: 9801830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biosynthetic gene cluster for the antitumor rebeccamycin: characterization and generation of indolocarbazole derivatives.
    Sánchez C; Butovich IA; Braña AF; Rohr J; Méndez C; Salas JA
    Chem Biol; 2002 Apr; 9(4):519-31. PubMed ID: 11983340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments of rebeccamycin analogues as topoisomerase I inhibitors and antitumor agents.
    Prudhomme M
    Curr Med Chem; 2000 Dec; 7(12):1189-212. PubMed ID: 11032967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11- dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity.
    Yoshinari T; Matsumoto M; Arakawa H; Okada H; Noguchi K; Suda H; Okura A; Nishimura S
    Cancer Res; 1995 Mar; 55(6):1310-5. PubMed ID: 7882328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA binding properties of the indolocarbazole antitumor drug NB-506.
    Carrasco C; Vezin H; Wilson WD; Ren J; Chaires JB; Bailly C
    Anticancer Drug Des; 2001; 16(2-3):99-107. PubMed ID: 11962518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dimers from dechlorinated rebeccamycin: synthesis, interaction with DNA, and antiproliferative activities.
    Marminon C; Facompré M; Bailly C; Hickman J; Pierré A; Pfeiffer B; Renard P; Prudhomme M
    Eur J Med Chem; 2002 May; 37(5):435-40. PubMed ID: 12008058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A DNA binding indolocarbazole disaccharide derivative remains highly cytotoxic without inhibiting topoisomerase I.
    Qu X; Chaires JB; Ohkubo M; Yoshinari T; Nishimura S; Bailly C
    Anticancer Drug Des; 1999 Oct; 14(5):433-42. PubMed ID: 10766298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production and biological activity of rebeccamycin, a novel antitumor agent.
    Bush JA; Long BH; Catino JJ; Bradner WT; Tomita K
    J Antibiot (Tokyo); 1987 May; 40(5):668-78. PubMed ID: 3112080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.